Here we report a series of close analogues of our recently published scaffold-based tripeptidomimetic CXCR4 antagonists, containing positively charged guanidino groups in R 1 and R 2 , and an aromatic group in R 3 . While contraction/elongation of the guanidine carrying side chains (R 1 and R 2 ) resulted in loss of activity, introduction of bromine in position 1 on the naphth-2-ylmethyl moiety (R 3 ) resulted in an EC50 of 61 µM (mixture of diastereoisomers) against wild-type CXCR4; thus, the antagonistic activity of these tripeptidomimetics seems to be amenable to optimization of the aromatic moiety. Moreover, for analogues carrying a naphth-2-ylmethyl substituent, we observed that a Pictet-Spengler like cyclization side reaction depended on the nature of the R 1 substituent.
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Introduction
The G protein coupled CXC chemokine receptor 4 (CXCR4) and its only known endogenous ligand, the 68-residue CXC chemokine ligand 12 (CXCL12), are involved in development and chemotaxis of leucocytes and lymphocytes, [1] [2] [3] as well as in embryogenesis by participating in vascularization of the gastrointestinal tract, 4 neural development 5 and haematopoiesis. 6 Since the CXCR4/CXCL12 axis also has been shown to have a pathological role in HIV, cancer and rheumatoid arthritis 7 CXCR4 is an attractive drug target, and several small-molecule CXCR4 antagonists have been described in the literature. [7] [8] [9] Plerixafor, the only small-molecule CXCR4 antagonist that has been approved so far, is used for mobilization of hematopoietic stem cells prior to autologous bone marrow transplantation in patients with Hodgkin disease, non-Hodgkin's lymphoma and multiple myeloma. 10, 11 Other small molecule CXCR4 antagonists are undergoing clinical trials; among them is the orally available AMD11070, which is investigated for its efficacy against HIV infection.
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In addition to the small-molecule antagonists, a large number of potent peptide antagonists for CXCR4 have been identified. [13] [14] [15] [16] [17] From a drug discovery perspective, a series of head-to-tail cyclized pentapeptides originally reported by Fujii and co-workers, 18 i. 
Results and discussion
2.1. Design and SAR -Our prototype hit compounds 3a and 3b contain Arg-side chains in R 1 and R 2 and a 2-naphthyl group with an ethylene spacer in R 3 ( Figure 1C ). Analogues with an amide group in the R 1 side chain can be conveniently synthesized by employing appropriately protected Cys residues as building blocks; however, since we previously found 4 and 5 ( Figure 1D ) to be inactive, 20 this strategy was abandoned. Instead, our synthetic strategy for the target compounds 6-12 in the current work (Table 1 ) was based on a racemic building block for introduction of the R 1 -side chain (see Chemistry below), giving both the (3R,6S,9aS) and the (3S,6S,9aR) diastereoisomer (a and b, respectively). The antagonistic potency of 6-12 on human CXCR4 was determined by a functional assay as previously described. First, compounds with two (6a and 6b) and four carbon atoms (7a and 7b) in the R 1 side chain were synthesized in order to determine the importance of side chain length. However, none of these four analogues showed biological activity, demonstrating that contraction/elongation of the R 1 side chain is unfavourable.
The length of the R 2 side chain was then increased by one carbon atom (8a and 8b), but this elongation resulted in loss of biologic activity. Compounds 9a and 9b, where a shorter R 1 side chain was incorporated to compensate the longer R 2 side chain, were also included; however, these compounds were similarly inactive.
Next, the R 3 side chain spacer was shortened to one carbon atom (10a/10b and 11a/11b).
Neither diastereoisomers of 10 or 11 were separable by preparative RP-HPLC, thus both were tested as the respective diastereomeric mixtures. Compound 10a,b did not show biological activity; however, the C-1 bromine-substituted analogue 11a,b had an EC50 value of 61 µM.
The bromine was introduced to avoid a suspected Pictet-Spengler type side reaction in the synthesis of these analogues (see Chemistry below), and since this substitution simultaneously affects the steric, electronic, and hydrophobic properties of the aromatic moiety, it is difficult to isolate the exact cause of the difference in activity between 10 and 11. Still, the fact that 11a,b is equipotent with 3b indicates that there is room for further optimization of the R 3 -side chain.
Finally, we included 12a and 12b, which are the 1-substituted isomers of 10a and 10b.
Compounds 12a and 12b were also tested as a mixture of diastereoisomers and did not show biological activity. For the synthesis of 6a,b -9a,b the required secondary amine 14 carrying the R 3 side chain was prepared by alkylation of primary amine 13 using bromoacetaldehyde dimethyl acetal in DMF (Scheme 2). Towards the synthesis of bicycles 10a,b, 11a,b and 12a,b secondary amines 18-20 were prepared from the appropriate aldehydes 15-17 by reductive amination through reaction with 2,2-dimethoxyethylamine followed by reduction with NaBH4 (Scheme 3). The different building blocks bearing the R 1 side chain were prepared starting from Bocprotected lactams 21-23 (Scheme 4). α-Methylenation through release of trifluoroacetate 23 gave Michael acceptors 24-26, which after reaction with Ph3CSH using Et3N as base gave the racemic Michael products 27-29 in good yields. Subsequent hydrolysis with LiOH gave the racemic carboxylic acids 30-32. All final compounds were purified by RP-HPLC, however the diastereoisomers of 10, 11 and 12 proved for all practical purposes to be inseparable. For 6-9, the two diastereoisomers that were formed were separable by RP-HPLC and analysis of the purified compounds by NMR spectroscopy clearly showed that they were single diastereoisomers. As the stereochemistry at C6 was fixed through incorporation of appropriately protected (S)-Arg, (S)-Orn or (S)-Lys (Scheme 5), the configuration at C3 and C9a (see Tables 1 and S1 ) could be determined by the 2D 1 H ROESY experiment as described previously. 20, 25 For all compounds that were Further, for the diastereoisomer that displayed the longest retention time of the pairs, strong cross-peaks between H9a and Hb/Hγ of the R 2 side-chain were always observed (see Table S1 for further details). These findings indicate that all compounds have the same configurations as reported for hit compounds 3a and 3b, 20 and that the (3R,6S,9aS) diastereoisomer (6a-9a) always eluted first and the (3S,6S,9aR) diastereoisomer (6b-9b) always eluted last from the C18-column for the separable diastereoisomeric pairs.
The bromine of 11a,b was originally introduced as a protecting group as we observed a side reaction in an attempted synthesis of bicycle 47 (Scheme 6). In our attempted synthesis of compound 47 (see SI for experimental details), compound 48
was instead the only product that could be isolated in pure form. Inspection of the 1 H NMR spectrum of the isolated compound quickly revealed that it was not the desired product as the signals in the aromatic region integrated to 6 protons instead of 7. The combined information obtained from the 2D 1 H-13 C HMBC and HSQC spectra revealed the presence of four quaternary carbon signals in the aromatic region. The structure of 48 was elucidated by extensive use of 2D NMR. Thus, it would seem that after formation of the N-acyliminium ion B (Scheme 1), the cyclization can take two different paths; either the thiol attacks the carbon atom in the double bond to yield the desired cyclization product, 21 or an aromatic substitution reaction, i.e. a Pictet Spengler-type reaction, takes place. 26 The 2D 1 H-1 H ROESY spectrum of 48 revealed no ROE between the bridge-head proton and the R 2 side chain, thus the nucleophilic attack on the acyliminium ion has occurred from the same side as the R 2 side chain.
In order to avoid the Pictet-Spengler product, bromine was introduced in the 1-position of the naphthalene group by starting with 1-bromo-2-naphthaldehyde (16) when preparing the building block bearing the R 3 side chain (Scheme 3). We envisioned that the bromine could be removed from the cyclized product by treatment with hydrogen gas in the presence of Pd/C. 27 The protection of the naphthalene proved however to be unnecessary, as the cyclization pathway was found to be highly dependent on the nature of the R 1 side chain (see SI for details) and cyclization of linear precursors 43, which contains a naphth-2-ylmethyl R 3 side chain and a three carbon spacer in the R 1 side chain, gave the desired bicycles as the major products (Scheme 7). Similar chemoselectivity was observed when the R 1 side chain was omitted (see SI for details), indicating that the electron withdrawing ammonium substituent (or Boc-protected amine if Boc deprotection is slower than cyclization) of the Nacyliminium ion formed from 46 (Scheme 6) decreases the nucleophilicity of the thiol. 
Conclusions
In summary, we have investigated close analogues of our earlier reported hit compounds based on a tripeptidomimetic scaffold for CXCR4 antagonists by varying the spacer length for the three side chains. Our results suggests that a three-carbon spacer is optimal for both of the guanidine carrying side chains, while the aromatic group in the R 3 position can still be optimized. Interestingly, we found that a side reaction of analogues carrying a naphth-2-ylmethyl substituent through a Pictet-Spengler like cyclization reaction was dependent on the nature of the R 1 substituent. Finally, introducing bromine in position 1 on the naphtha-2-ylmethyl moiety gave a mixture of inseparable diastereoisomers with an EC50 of 61 µM against wild-type CXCR4, thus the antagonistic activity of these tripeptidomimetics seems to be amenable to changes on the aromatic moiety. Fractions of equal purity were pooled and lyophilized. All tested compounds were analysed by RP-HPLC and found to be of > 95% purity (sum of isomers for inseparable diastereoisomers).
To a stirring solution of 2-(naphthalen-2-yl)ethan-1-amine (0.39 g, 2.28 mmol) in anhydrous DMF (10 mL), K2CO3 (0.32 g, 2.34 mmol) and bromoacetaldehyde dimethyl acetal (0.38 mL, 260.1651.
2,2-Dimethoxy-N-(naphthalen-2-ylmethyl)ethan-1-amine (18)
A mixture of 2-naphthaldehyde (845 mg, 5.4 mmol) and aminoacetaldehyde dimethyl acetal (0.6 mL, 5.5 mmol) was heated at 100 °C for 20 min and then cooled to room temperature.
The reaction mixture was then diluted with EtOH (4 mL) and NaBH4 (207 mg, 5.5 mmol) was added in small portions to the stirring mixture. The reaction mixture was stirred for 22 h before the EtOH was removed and the residue was portioned between H2O (10 mL) and EtOAc (40 mL). The organic phase was washed with H2O (2 x 10 mL), dried over MgSO4, filtered and concentrated to give the crude product as yellow oil ( 
The title compound was prepared from 1-bromo-2-naphthaldehyde (202 mg, 0.9 mmol)
following the protocol described for 18 above. The crude product (yellowish oil, 243 mg) was purified by flash column chromatography on silica gel (EtOAc) to give the title compound as yellowish oil (124 mg, 44% The title compound was prepared from 22 (933 mg, 4.7 mmol) following the protocol described for 24 above, except that stirring in the second step was carried out at 80 °C for 2 h The title compound was prepared from 25 (379 mg, 1.8 mmol) following the protocol The title compound was prepared from lactam 28 (348 mg, 0.7 mmol) following the protocol To a stirring solution of the secondary amine (1.40 mmol) in dry CH2Cl2 (5 mL) was added Fmoc-protected amino acid (1.40 mmol), HATU (545, 1.43 mmol) and DIPEA (0.75 mL, 4.31 mmol). The reaction mixture was stirred for 23 h before the solvent was removed and the residue was partitioned between H2O (10 mL) and EtOAc (10 mL). The aqueous phase was extracted with EtOAc (2 x 10 mL) and the combined organic phases were washed with 1 M KHSO4 (20 mL), H2O (20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic phase was dried over MgSO4, filtered and concentrated to yield the crude product, which was purified by flash column chromatography on silica gel. (20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic phase was dried over MgSO4, filtered and concentrated to yield the crude product, which was purified by flash column chromatography on silica. 
tert-Butyl (4-(((S
The title compound was prepared from carboxylic acid 31 (244 mg, 0.48 mmol) and Fmoc- 
The title compound was prepared from carboxylic acid 31 (112 mg, 0. 
Linear precursor 41 (158 mg, 0.16 mmol) was deprotected and cyclized following the general procedure. The crude product (212 mg) was dissolved in dry DMF (10 mL) and 1H-pyrazole-1-carboxamidine hydrochloride (132 mg, 0.90 mmol) and DIPEA (0.16 mL, 0.90 mmol) were added. The mixture was stirred for 72 h at room temperature during which the reaction was monitored by RP-HPLC. Diethyl ether (40 mL) was then added and the mixture was cooled to 4 °C and stirred for an additional hour, resulting in the precipitation of a brown oil (163 mg).
The crude product was purified by semi-preparative RP-HPLC to give the title compound as a white fluffy solid (5.5 mg, 9% Linear precursor 42 (185 mg, 0.19 mmol) was deprotected and cyclized following the general procedure. The crude product (188 mg) was dissolved in dry DMF (10 mL) and 1H-pyrazole-1-carboxamidine hydrochloride (121 mg, 0.83 mmol) and DIPEA (0.14 mL, 0.83 mmol) were added. The mixture was stirred for 90 h at room temperature during which the reaction was monitored by RP-HPLC. Diethyl ether (40 mL) was then added and the mixture was cooled to 4 °C and stirred for an additional hour, resulting in the precipitation of a brown oil (173 mg).
The crude product was purified by semi-preparative RP-HPLC to give the title compound as a white fluffy solid (4.7 mg, 6% 
